Samsung Biologics Co.,Ltd.
207940
Peringkat dalam Saham
#496
Samsung Biologics Co.,Ltd., established in 2011 and headquartered in Incheon,... Samsung Biologics Co.,Ltd., established in 2011 and headquartered in Incheon, South Korea, provides contract services for biopharmaceutical products. The company's operations are divided into two main segments: Contract Manufacturing Organization (CMO) and Contract Development Organization (CDO). Its CDO services cover areas such as cell line development, optimization of upstream and downstream processes, and the formulation of analytical methods and final products. For CMO, the company offers aseptic filling, lyophilization, finishing, storage, shipping, and various associated support services. Additionally, it delivers comprehensive quality assurance, quality control, biosafety, and analytical testing. Samsung Biologics is also involved in creating and launching biosimilar drugs, alongside manufacturing mammalian cell-based antibody medications.
Harga Saham
$1,028.49
Kapitalisasi Pasar
$47.88B
Perubahan (1 hari)
-3.67%
Perubahan (1 tahun)
-18.37%
Negara
KR
Perdagangan Samsung Biologics Co.,Ltd. (207940)
Kategori
Healthcare
Laba untuk Samsung Biologics Co.,Ltd. (207940)
Laba pada 2026 TTM: 0
Menurut laporan keuangan terbaru dari Samsung Biologics Co.,Ltd., laba saat ini perusahaan adalah 0. Pada tahun 2026, perusahaan memperoleh laba sebesar 0, sama dengan laba tahun 2026 sebesar 0. Laba yang ditampilkan di halaman ini adalah laba sebelum bunga dan pajak, atau disebut juga EBIT.
Riwayat laba untuk Samsung Biologics Co.,Ltd. dari 2014 hingga 2026
Laba pada akhir setiap tahun
| Tahun | Laba | Mengubah |
|---|---|---|
| 2025 | $1.47B | 55.69% |
| 2024 | $941.97M | 8.88% |
| 2023 | $865.17M | 8.20% |
| 2022 | $799.60M | 69.37% |
| 2021 | $472.11M | 92.69% |
| 2020 | $245.01M | 82.02% |
| 2019 | $134.61M | -50.53% |
| 2018 | $272.09M | -350.00% |
| 2017 | $-108.84M | -43.17% |
| 2016 | $-191.50M | -109.05% |
| 2015 | $2.12B | -2,423.97% |
| 2014 | $-91.10M | 0.00% |
Laba untuk perusahaan serupa atau pesaing
| Perusahaan | Laba | Perbedaan Laba | Negara |
|---|---|---|---|
| $5.27B | - |
US
|
|
| $-3.09B | - |
US
|
|
| $-4.02B | - |
AU
|
|
| $3.01B | - |
BE
|
|
| $1.95B | - |
NL
|
